Cargando…
Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408039/ https://www.ncbi.nlm.nih.gov/pubmed/32708409 http://dx.doi.org/10.3390/pharmaceutics12070677 |
_version_ | 1783567745274609664 |
---|---|
author | Nezvalova-Henriksen, Katerina Nilsson, Niklas Østerberg, Camilla Tomine Staven Berge, Vigdis Tho, Ingunn |
author_facet | Nezvalova-Henriksen, Katerina Nilsson, Niklas Østerberg, Camilla Tomine Staven Berge, Vigdis Tho, Ingunn |
author_sort | Nezvalova-Henriksen, Katerina |
collection | PubMed |
description | Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-immune reactions. Information on intravenous compatibility is scarce. Our aim was to analyse the compatibility of Numeta G13E with paracetamol, vancomycin and fentanyl because of the frequency of their use. A panel of methods was chosen to assess precipitation (sub-visual particle counting, turbidity measurement, Tyndall beam effect and pH measurement) and emulsion destabilization (mean droplet diameter measurement and sub-visual counting of oil droplets, followed by estimation of PFAT5 (percentage of fat residing in globules larger than 5 µm) and pH measurement). Samples in clinically relevant mixing ratios were tested immediately and after 4 h. All samples of drugs mixed with Numeta G13E were compared to unmixed controls. None of the tested drugs precipitated in contact with Numeta G13E, and we did not see any sign of emulsion destabilization when clinically relevant mixing ratios were applied. These results are reassuring. However, when contact time exceeds the established norm, caution in the form of filter utilisation and close inspection is advised. |
format | Online Article Text |
id | pubmed-7408039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74080392020-08-12 Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care Nezvalova-Henriksen, Katerina Nilsson, Niklas Østerberg, Camilla Tomine Staven Berge, Vigdis Tho, Ingunn Pharmaceutics Article Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-immune reactions. Information on intravenous compatibility is scarce. Our aim was to analyse the compatibility of Numeta G13E with paracetamol, vancomycin and fentanyl because of the frequency of their use. A panel of methods was chosen to assess precipitation (sub-visual particle counting, turbidity measurement, Tyndall beam effect and pH measurement) and emulsion destabilization (mean droplet diameter measurement and sub-visual counting of oil droplets, followed by estimation of PFAT5 (percentage of fat residing in globules larger than 5 µm) and pH measurement). Samples in clinically relevant mixing ratios were tested immediately and after 4 h. All samples of drugs mixed with Numeta G13E were compared to unmixed controls. None of the tested drugs precipitated in contact with Numeta G13E, and we did not see any sign of emulsion destabilization when clinically relevant mixing ratios were applied. These results are reassuring. However, when contact time exceeds the established norm, caution in the form of filter utilisation and close inspection is advised. MDPI 2020-07-18 /pmc/articles/PMC7408039/ /pubmed/32708409 http://dx.doi.org/10.3390/pharmaceutics12070677 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nezvalova-Henriksen, Katerina Nilsson, Niklas Østerberg, Camilla Tomine Staven Berge, Vigdis Tho, Ingunn Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care |
title | Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care |
title_full | Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care |
title_fullStr | Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care |
title_full_unstemmed | Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care |
title_short | Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care |
title_sort | y-site physical compatibility of numeta g13e with drugs frequently used at neonatal intensive care |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408039/ https://www.ncbi.nlm.nih.gov/pubmed/32708409 http://dx.doi.org/10.3390/pharmaceutics12070677 |
work_keys_str_mv | AT nezvalovahenriksenkaterina ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare AT nilssonniklas ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare AT østerbergcamillatomine ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare AT stavenbergevigdis ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare AT thoingunn ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare |